## Amendments to the claims:

This listing of claims will replace all prior versions and listings of claims in the application:

(Currently Amended) A composition for transdermal administration of at least one therapeutically active compound or nutrient, said composition consisting of:

at least one item selected from the group consisting of at least one therapeutically active compound and at least one nutrient, <u>wherein the therapeutically active compound and the at least</u> one nutrient is an ionic compound;

a non-oily emulsion which is a mixture of lecithin, bile salts and cholesterol in water, wherein the ratio by weight of lecithin, bile salts and cholesterol is 2:1:1; and

an optional organic sulfur compound.

- (Canceled).
- (Currently amended) The composition for transdermal administration according to claim 2 1, wherein the ionic compound is a metal ion.
- (Currently amended) The A composition according to claim 1, wherein for transdermal administration of at least one therapeutically active compound, said composition consisting of:
- at least one therapeutically active compound, wherein said therapeutically active compound is a polypeptide;
- a non-oily emulsion which is a mixture of lecithin, bile salts and cholesterol in water, wherein the ratio by weight of lecithin, bile salts and cholesterol is 2:1:1; and an optional organic sulfur compound,
- (Previously presented) The composition according to claim 4, wherein said polypeptide has a molecular weight of up to 7000 kDa.
- (Currently amended) The A composition according to claim 1, wherein for transdermal administration of at least one therapeutically active compound, said composition consisting of:

PHX/2290154.1 2

AMENDMENT UNDER 37 C.F.R § 1.116 IN RESPONSE TO FINAL OFFICE ACTION Docket No. 15872.212
Title: "A Platform for Transdermal Formulations (PTF)"
U.S. Application No. 10/511.463

at least one therapeutically active compound, wherein said therapeutically active compound is selected from the group consisting of antiparasitic agents, anthelmintic drugs and antibiotic drugs, used for the treatment of humans, livestock or domestic animals;

a non-oily emulsion which is a mixture of lecithin, bile salts and cholesterol in water, wherein the ratio by weight of lecithin, bile salts and cholesterol is 2:1:1; and

an optional organic sulfur compound.

## 7.-11. (Canceled).

- 12. (Currently amended) The composition according to claim  $\frac{11}{2}$ , wherein the organic sulfur compound is present in said composition in an amount of 2-30% (w/v), in relation to the non-oily emulsion.
- (Currently amended) The composition according to claim #1 1, wherein the
  organic sulfur compound is selected from the group consisting of dimethylsulfoxide,
  methylsulfonylmethane, 2,3-dimethylsulfolane, 2,4-dimethylsulfolane and sodium lauryl sulfate.

## 14-15 (Canceled).

- 16. (Previously presented) The composition according to claim 12, wherein the organic sulfur compound is present in said composition in an amount of 4-25% (w/v), in relation to said non-oily emulsion.
- 17. (Previously Presented) A method for manufacturing a cream, gel, lotion, suppository, ointment or patch (transdermal therapeutic system), wherein a composition according to claim 1 is used, comprising the step of soaking said cream, gel, lotion, suppository, ointment or patch with an emulsion of the composition according to claim 1.
- 18. (Previously presented) A method for transdermal administration of therapeutically active compounds or nutrient, wherein a composition consisting of at least one item selected from the group consisting of at least one therapeutically active compound and at least one nutrient, a non-oily emulsion which is a mixture of lecithin, bile salts and cholesterol in water, and an optional organic sulfur compound is used, said method comprising the step of soaking a cream, gel, lotion, suppository, ointment or patch with an emulsion of said

PHX/2290154.1 3

AMENDMENT UNDER 37 C.F.R § 1.116 IN RESPONSE TO FINAL OFFICE ACTION Docket No. 15872.212
Title: "A Platform for Transdermal Formulations (PTF)"
U.S. Application No. 10/511.463

composition and applying said cream, gel, lotion, suppository, ointment or patch having said emulsion of said composition to a subject.

- (New) The composition according to claim 4, wherein the organic sulfur compound is present in said composition in an amount of 2-30% (w/v), in relation to the non-oily emulsion
- (New) The composition according to claim 6, wherein the organic sulfur compound is present in said composition in an amount of 2-30% (w/v), in relation to the non-oily emulsion.
- (New) The composition according to claim 4, wherein the organic sulfur compound is selected from the group consisting of dimethylsulfoxide, methylsulfonylmethane,
   2.3-dimethylsulfolane,
   2.4-dimethylsulfolane and sodium lauryl sulfate.
- 22. (New) The composition according to claim 6, wherein the organic sulfur compound is selected from the group consisting of dimethylsulfoxide, methylsulfonylmethane, 2,3-dimethylsulfolane, 2,4-dimethylsulfolane and sodium lauryl sulfate.
- 23. (New) A method for manufacturing a cream, gel, lotion, suppository, ointment or patch (transdermal therapeutic system), comprising the step of soaking said cream, gel, lotion, suppository, ointment or patch with an emulsion of the composition according to claim 4.
- 24. (New) A method for manufacturing a cream, gel, lotion, suppository, ointment or patch (transdermal therapeutic system), comprising the step of soaking said cream, gel, lotion, suppository, ointment or patch with an emulsion of the composition according to claim 6.

PHX/2290154.1 4